Objective-Circulating levels of C-reactive protein (CRP) are associated with an increased risk of coronary artery disease (CAD), stroke, and peripheral artery disease (PAD). Observational and experimental evidence suggest that CRP might differentially predict fatal and nonfatal cardiovascular events. Here, we sought to determine the predictive value of CRP for fatal and nonfatal CAD, stroke, or PAD. Approach and Results-CRP levels were measured in 18 450 apparently healthy participants in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk cohort. Cox proportional hazards models were used to quantify the association between CRP levels and fatal and nonfatal CAD events, strokes, and PAD events. Bootstrapping was applied to test for significant differences between the risk of fatal and nonfatal events. During 208 485 person-years at risk, 2915 CAD events, 361 strokes, and 657 PAD events occurred. CRP was associated with fatal and nonfatal CAD events and nonfatal PAD events. When adding CRP to predictive risk models for fatal and nonfatal events corrected for known cardiovascular risk factors, the net reclassification index was 2.1% for fatal and 1.9% for nonfatal events. Multivariate adjusted hazard ratios for fatal CAD events (hazard ratio, 1.36; 95% confidence interval, 1.27-1.46) differed significantly (mean difference, 13%; 95% confidence interval, 5.1%-21.9%; P<0.001) from the multivariate adjusted hazard ratio for nonfatal CAD events (hazard ratio, 1.21; 95% confidence interval, 1.15-1.26). Conclusions-In the EPIC-Norfolk cohort, CRP was associated with fatal and nonfatal CAD events, as well as nonfatal PAD events. Adding CRP to risk stratification models resulted in a small improvement in classification for both fatal and nonfatal events. Importantly, CRP was significantly more strongly associated with fatal CAD events than with nonfatal CAD events. (Arterioscler Thromb Vasc Biol. 2013;33:2888-2894.) The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
A therosclerosis is a systemic, low-grade inflammatory disease 1-3 that may result in a variety of clinical complications, including coronary artery disease (CAD), stroke, and peripheral artery disease (PAD). C-reactive protein (CRP) is an acute phase protein and a member of the family of pentraxins. It is predominantly produced in the liver, and its plasma concentration can rise up to 1000-fold during serious infections or major tissue damage. 4 CRP is present in the atherosclerotic plaque, 5 where it colocalizes with monocytes, monocyte-derived macrophages, and lipoproteins. 6, 7 The presence of CRP within the atherosclerotic plaque, combined with the proatherogenic effects attributed to CRP, [8] [9] [10] [11] [12] has fueled the concept that CRP may be a causal factor in atherogenesis. 12 However, others have refuted a causal relationship by observing that CRP polymorphisms associated with increased CRP levels were not proportionally associated with an increased risk of CAD. 13, 14 Nonetheless, the association between CRP levels and the risk of future myocardial infarction or ischemic stroke has been studied extensively. In a large meta-analysis of 54 long-term prospective studies with individual records of 160 309 people without a history of vascular disease, CRP was strongly associated with the risk of CAD and ischemic stroke. 15 However, these studies usually examined associations between circulating CRP levels and the sum of both fatal and nonfatal cardiovascular events as a combined outcome. If CRP is differentially associated with fatal and nonfatal CAD, the associations between CRP and fatal cardiovascular events might have been underestimated. Recently, CRP was shown to have a stronger association with fatal than nonfatal vascular events in the Prospective Study of Pravastatin in the Elderly at Risk trial that enrolled elderly men and women with a mean age of 76 years. 16, 17 Both in vitro and in vivo data indicate that not only inflammation in general but also CRP itself can aggravate myocardial infarction promoting more severe cardiovascular events. [18] [19] [20] [21] We therefore hypothesized that CRP is more strongly associated with fatal compared with nonfatal CAD events, strokes, and PAD events in the general population. We tested this hypothesis in the EPIC-Norfolk prospective population study. Here, we present our data.
Materials and Methods
Materials and methods are available in the online-only Supplement.
Results
CRP levels were available in 18 450 participants. In Table 1 , baseline characteristics and the calculated Framingham Risk Score are listed for the study participants. The mean Framingham Risk Score was 12.8±10.8 indicating a 10-year average risk of 12.8% for a CAD event. Table 2 shows the association between CRP levels and traditional cardiovascular risk factors. As expected, CRP levels were associated with all major traditional risk factors for cardiovascular disease (CVD). Body mass index, waist circumference, age, and triglycerides had the strongest correlation with CRP serum concentrations. Hazard ratio (HRs) for all fatal cardiovascular events were higher compared with HRs for all nonfatal cardiovascular events, but none reached our predefined Bonferroni corrected P value (P=0.01) Table 3 shows the number and percentages of fatal and nonfatal CAD, stroke, and PAD-related events for each CRP quartile.
CRP Levels and CAD Events
The unadjusted HR for 1 mg/L CRP increment was 1.67 (95% confidence interval [CI], 1.57-1.77) for fatal CAD events and 1.42 (95% CI, 1.36-1.47) for nonfatal CAD events ( Table 3 ). The multivariate adjusted HR for fatal CAD was 1.36 (95% CI, 1.27-1.46) and for nonfatal CAD events was 1.21 (95% CI, 1.15-1.26). HRs for the risk of fatal and nonfatal CAD events according to CRP quartiles are displayed in Table 5 . The multivariate adjusted HRs for fatal CAD events were significantly different from the multivariate adjusted HRs for nonfatal CAD events (mean difference, 13%; 95% CI, 5.1%-21.9%; P<0.001).
CRP Levels and Stroke
The unadjusted HR for 1 mg/L CRP increment was 1.59 (95% CI, 1.24-2.04) for fatal stroke and 1.38 (95% CI, 1.23-1.52) for nonfatal stroke. The multivariate adjusted HR for fatal stroke and nonfatal stroke did not reach our predefined multiple testing P value. HRs for the risk of fatal and nonfatal stroke according to CRP quartiles are displayed in Table 5 . The multivariate adjusted HR for fatal stroke and nonfatal stroke did not differ significantly (mean difference, 21.0%; 95% CI, −11.5% to 62.6%; P=0.23).
CRP Levels and PAD
The unadjusted HR for 1 mg/L CRP increment was 1.86 (95% CI, 1.19-2.92) for fatal PAD events and 1.59 (95% CI, 1.49-1.70) for nonfatal CAD events. The multivariate adjusted HR for nonfatal PAD events remained statistically significant (HR, 1.36; 95% CI, 1.26-1.48), whereas for fatal PAD events, the multivariate adjusted HR lost statistical significance. HRs for the risk of fatal and nonfatal PAD events according to CRP quartiles are displayed in Table 4 . The multivariate adjusted HRs for fatal PAD did not differ significantly compared with that for nonfatal PAD events (mean difference, 6.6%; 95% CI, −42% to 74.9%; P=0.77). Figure 1 displays the event-free survival curves for stroke, CAD, and PAD according to CRP concentrations.
CRP and Fatal Versus Nonfatal Cardiovascular Prediction Performance
The C statistic for all combined fatal CAD, stroke, and PAD events was 0.82 (95% CI, 0.81-0.83; P<0.001), whereas the C statistic for nonfatal events was 0.76 (95% CI, 0.75-0.77; P<0.001). Figure 2 displays the receiver operating characteristic curve for fatal and nonfatal cardiovascular events. Data are presented as mean±SD or numbers (percentage). Triglyceride and C-reactive protein are presented as median with the 25th to 75th percentile. HDL indicates high-density lipoprotein; and LDL, low-density lipoprotein. December 2013 established CVD risk factors to predict fatal cardiovascular events resulted in 126 individuals being correctly reclassified into a higher risk category, as compared with the model without CRP. A total of 112 individuals were incorrectly reclassified into a lower risk category. Similarly, 1121 individuals who did not develop CVD during follow-up were correctly reclassified into a lower category, whereas 897 individuals were incorrectly reclassified into a higher category. The net effect was a correct reclassification in 224 fatal events. The net reclassification improvement was 2.1% (95% CI, 0.7%-3.5%; P<0.001).
The use of CRP in addition to established CVD risk factors to predict nonfatal cardiovascular events resulted in 111 individuals being correctly reclassified into a higher risk category, as compared with the model without CRP. A total of 98 individuals were incorrectly reclassified into a Data are presented as mean±SD or number (percentage). Triglycerides and CRP are presented as median with the 25th to 75th percentile and log transformed before analysis. For triglycerides, the Spearman correlation between CRP serum concentration and triglycerides is presented. CRP indicates C-reactive protein; HDL, highdensity lipoprotein; LDL, low-density lipoprotein; and R, Pearson correlation between log-transformed CRP serum concentration and risk factors.
*P value for linearity between CRP serum concentration quartiles and risk factor levels. †P value corresponding to R. Distribution of events (number and percentage) across CRP quartiles. Mean follow-up±SD is given in years and calculated for overall mortality. CRP indicates C-reactive protein lower risk category. Similarly, 911 individuals who did not develop CVD during follow-up were correctly reclassified into a lower category, whereas 703 individuals were incorrectly reclassified into a higher category. The net effect was a correct reclassification in 13 nonfatal events. The net reclassification improvement was 1.9% (95% CI, 0.6%-3.3%; P<0.001). To further determine the addition of CRP to the model to predict CVD risk, the integrated discrimination index was calculated. The integrated discrimination index for fatal cardiovascular events was 0.008 (95% CI, 0.006-0.010; P<0.001), whereas the integrated discrimination index for nonfatal cardiovascular events was 0.003 (95% CI, 0.002-0.004; P<0.001).
Discussion
We confirm the findings from previous studies that elevated CRP levels are associated with an increased risk of future CAD events in apparently healthy individuals. In addition, we show that CRP levels are also associated with PAD events. More importantly, we observed that the association with CRP levels is stronger for fatal CAD events compared with nonfatal CAD events. The latter may imply a pathological role for either CRP itself or inflammation in general in promoting more severe cardiovascular events, associated with an increased propensity of fatal events.
Several publications have reported an association between CRP levels and major cardiovascular events in patients with PAD. [22] [23] [24] However, data on the association between CRP levels and risk of future peripheral vascular disease are scarce. Only a few studies have reported data on this outcome with relatively few cases compared with similar studies reporting coronary and cerebrovascular endpoints. One nested case-control study reported a relative risk of PAD of 2.8 (95% CI, 1.3-5.9) for people in the highest CRP quartile compared with the lowest CRP quartile. 25 Of the 1519 healthy individuals in the Edinburgh Artery Study, 208 subjects developed symptomatic PAD. CRP was significantly (P<0.01) associated with PAD, with a corresponding HR of 1.30 (95% CI, 1.1-1.6). 26 Our finding of an association between CRP levels and fatal PAD events requires the following considerations. There were only few fatal PAD events, limiting the statistical power for such an analysis. Also, the combined group of PAD diseases was diagnosed on the basis of International Classification of Diseases, Tenth Revision codes I70 to I73, which may have included several cases of nonatherosclerotic diseases, such as Raynaud disease or vasculitis. Although we expect the number of such diagnoses to be low compared with atherosclerotic PAD, we cannot exclude the possibility that this may have confounded the PAD results. Our observation that CRP levels are more strongly associated with fatal CAD events compared with nonfatal CAD events is underlined by the observation that CRP adds more discriminative power to the fatal compared with the nonfatal predictive risk model as demonstrated by the comparative predictive risk analyses. These findings may have different explanations. First, inflammation in general can promote more serious atherothrombotic reactions comprising thrombosis, endothelial dysfunction, and vasoconstriction, thereby increasing the likelihood of a fatal outcome following plaque rupture. [27] [28] [29] [30] In line, serum levels of inflammatory markers obtained during an acute setting are associated with an adverse outcome. 30 These findings are corroborated by association studies showing that cardiovascular mortality is increased after an acute respiratory tract infection or urinary tract infections in the general population with odds ratios up to 4-fold in the first 2 weeks after the infective episode 31 and data suggesting an activation of the coagulation system by inflammatory cytokines. 32 Second, our findings are also compatible with the hypothesis that in the case of an acute coronary syndrome, CRP contributes to a more severe outcome by aggravating myocardial cell death and contributing to a wider area of tissue loss. This concept is supported by studies reporting that CRP as well as CRPcomplement complexes accumulate in infarcted human myocardium. 19, 33 CRP bound to ischemic cardiomyocytes has been shown to recruit complement factor 1a and thereby activate the complement system, 20 and injection of human CRP into rats after ligation of the coronary artery enhanced infarct size by ≈40%. This concept is further corroborated by the observation that in vivo complement depletion markedly reduced infarct size, even when initiated up to 2 hours after coronary ligation. 21 When interpreting the results of our study, several aspects need to be taken into account. An important strength of this study is the large number of cardiovascular outcomes, and PAD outcomes in particular. However, it must be noted that the defined outcomes of CAD, stroke, and PAD events may have included some nonatherosclerotic events, although the number of these events is only limited. Also, no changes in lipid-lowering therapy were recorded during follow-up. Statins decrease systemic CRP levels, and the use of such medication could have altered CRP levels and the inherent cardiovascular risk. 34 In summary, we confirm a strong and independent association between elevated CRP levels and an increased risk of CAD and PAD outcomes. Importantly, CRP levels were more strongly associated with the risk of fatal CAD events compared with nonfatal CAD events. This study lends further support to investigate the efficacy and safety of targeting inflammation per se for the prevention of cardiovascular events.
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C-reactive protein (CRP) has been widely acknowledged as an independent risk factor for cardiovascular disease. The association between circulating CRP levels and cardiovascular disease end points are most often based on composite end points including both fatal and nonfatal events. Here, we examined a possible differential association between CRP and fatal or nonfatal events. We demonstrate that elevated levels of CRP increase the risk of more severe cardiovascular events. These results suggest that elevated levels of CRP might contribute directly to a more severe outcome of cardiovascular events. These data lend further support to investigate the efficacy and safety of targeting inflammation to reduce the severity of cardiovascular events.
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